Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
AssigneeNova Pharmaceutical Corporation
InventorsWaclaw J. Rzeszotarski, Donald J. Kyle
Life of this patent
Estimating the term…
Loading patent…
AssigneeNova Pharmaceutical Corporation
InventorsWaclaw J. Rzeszotarski, Donald J. Kyle
Estimating the term…
The invention pertains to novel, potent anticonvulsants, analgesics, cognition enhancers and neuroprotectants achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to .omega.-[2-(phosphonoalkylenyl)-cycloalkyl]-2-aminoalkanoic acids having general formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of hydrogen, lower alkyl (C.sub.1 to C.sub.6), alkyl (C.sub.7 to C.sub.12), fatty acid chain (C.sub.13 to C.sub.24), aryl, aralkyl, hydroxyl; the stereoisomers being in their resolved or racemic form; n and m=0,1,2 or 3; z=0,1 or 2; the cycloalkyl ring being replaced with the cycloalkenyl ring; and the pharmaceutically acceptable salts and derivatives thereof.
A potent selective excitatory amino acid neurotransmitter receptor antagonist having the general formula:
A potent, selective excitatory amino acid neurotransmitter receptor antagonist having the general formula:
A potent, selective excitatory amino acid neurotransmitter receptor antagonist having the general formula:
A potent selective excitatory amino acid neurotransmitter receptor antagonist having the general formula:
Dependencies are inferred from the claim text.